Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azilsartan vs valsartan crossover trial in IgA nephropathy with hypertension
ChiCTR2300076082Phase 4Not yet recruiting
- Sponsor
- Chinese Cardiovascular Association-HX Fund
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of azilsartan in IgA nephropathy (IgAN) and hypertension (HTN) (2 arms), sponsored by Chinese Cardiovascular Association-HX Fund. Primary endpoint: Urine albumin-to-creatinine ratio (ACR). Planned start Aug 2023; status: not yet recruiting.
02
Drugs
azilsartan
03
Conditions
IgA nephropathy (IgAN)hypertension (HTN)
Beyond the preview
Go deeper on ChiCTR2300076082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076082.